Latest Conference Articles

September 9th 2021, 4:35pm

International Myeloma Society Annual Meeting

Iberdomide combined with dexamethasone and either daratumumab, bortezomib, or carfilzomib showed efficacy and tolerability in patients with relapsed or refractory multiple myeloma.

September 9th 2021, 3:42pm

IASLC World Conference on Lung Cancer

Updated data from a phase 2 trial presented at the 2021 World Conference on Lung Cancer showed that neoadjuvant osimertinib induced a pathologic complete response among patients with surgically resectable EGFR-mutant non–small cell lung cancer.

September 9th 2021, 3:30pm

IASLC World Conference on Lung Cancer

Mobocertinib demonstrated clinical activity in previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer whether or not they received a prior PD-1/PD-L1 inhibitor.

September 8th 2021, 10:28pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The cure rate for patients with T-cell acute lymphoblastic leukemia has improved dramatically over the past few decades, with outcomes becoming comparable to what is observed in those with B-cell acute lymphoblastic leukemia.

September 8th 2021, 10:00pm

IASLC World Conference on Lung Cancer

The combination of ado-trastuzumab emtansine and osimertinib demonstrated minimal antitumor effects on patients with EGFR-mutated non–small cell lung cancer, according to interim data of the phase 2 TRAEMOS trial.

September 8th 2021, 9:27pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Jorge E. Cortes, MD, discusses emerging therapies in chronic myeloid leukemia.

September 8th 2021, 8:52pm

IASLC World Conference on Lung Cancer

Selpercatinib demonstrated robust and durable efficacy with a favorable safety profile in Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.

September 8th 2021, 7:55pm

IASLC World Conference on Lung Cancer

Sotorasib elicited systemic durable anticancer activity with intracranial complete responses and continued intracranial stabilization in patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases previously treated with radiation or surgery.

September 8th 2021, 7:25pm

IASLC World Conference on Lung Cancer

Approximately 20% of patients with malignant pleural mesothelioma were diagnosed with COVID-19 during the first year of the pandemic at the Vall d’Hebron University Hospital, leading to a high hospitalization and mortality rate.

September 8th 2021, 6:49pm

IASLC World Conference on Lung Cancer

Tislelizumab plus chemotherapy demonstrated clinically meaningful improvements in progression-free survival vs standard of care chemotherapy as a first-line treatment for patients with stage IIIB and those with stage IV advanced squamous non–small cell lung cancer.

September 8th 2021, 6:42pm

IASLC World Conference on Lung Cancer

The combination of osimertinib plus pelcitoclax demonstrated an acceptable safety profile and preliminary efficacy at the recommended phase 2 dose in patients with EGFR-positive non–small cell lung cancer that is resistant to third-generation EGFR inhibitors or treatment naïve.

September 8th 2021, 6:35pm

Society of Hematologic Oncology Annual Meeting (SOHO)

In recent years, significant advances have been made regarding the treatment of patients with chronic graft-vs-host disease, with investigators developing an understanding of the pathophysiology of the disease, as well as how to integrate novel treatment modalities.

September 8th 2021, 6:11pm

IASLC World Conference on Lung Cancer

In patients with advanced RET fusion–positive non-small cell lung cancer, pralsetinib demonstrated promising results regardless of previous therapies.

September 8th 2021, 3:53pm

IASLC World Conference on Lung Cancer

Mobocertinib improved patient-reported outcomes in those with previously treated non–small cell lung cancer whose tumors harbored EGFR exon 20 insertion mutations.

September 7th 2021, 5:21pm

International Liver Cancer Association Annual Conference

ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.

September 7th 2021, 1:02pm

International Liver Cancer Association Annual Conference

Nivolumab elicited a prolonged clinical benefit in patients with advanced hepatocellular carcinoma regardless of prior sorafenib.

September 5th 2021, 8:27pm

International Liver Cancer Association Annual Conference

Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.

September 5th 2021, 4:34pm

International Liver Cancer Association Annual Conference

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).

September 5th 2021, 4:05pm

International Liver Cancer Association Annual Conference

The combination of atezolizumab and bevacizumab elicited an improved overall survival benefit compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma, according to findings from an exploratory subgroup analysis of the phase 3 IMbrave150 trial.

September 5th 2021, 12:04am

International Liver Cancer Association Annual Conference

Biomarkers of response to immunotherapy, characterized by high interferon signaling and expression of MHC-II related genes, predicted for improved survival in patients with advanced hepatocellular carcinoma following immediate treatment with a PD-1 inhibitor but not in those who had first received treatment with a TKI.